- Maddox TM
- Januzzi JL
- Allen LA
- Breathett K
- Butler J
- Davis LL
- et al.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee.J Am Coll Cardiol. 2021; 77: 772-810
- The continuous heart failure spectrum: moving beyond an ejection fraction classification.Eur Heart J. 2019; 40: 2155-2163
- Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?.Eur Heart J. 2020; 41: 1249-1257
- Left ventricular geometry as a major determinant of left ventricular ejection fraction: physiological considerations and clinical implications.Eur J Heart Fail. 2018; 20: 436-444
- Prognostic value of peak stress cardiac power in patients with normal ejection fraction undergoing exercise stress echocardiography.Eur Heart J. 2021; 42: 776-785
- Cardiovascular autonomic disturbances in heart failure with preserved ejection fraction.Can J Cardiol. 2020 Dec 10; ([Epub ahead of print])
- Sacubitril/valsartan across the spectrum of ejection fraction in heart failure.Circulation. 2020; 141: 352-361
- Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis.ESC Heart Fail. 2020; 7: 3298-3309
Filippos Triposkiadis reports research support and honoraria from Amgen, Bayer, Boehringer Ingelheim, Elpen, Lilly, Menarini, Merck, Novartis, Sanofi, Servier, Vianex, and WinMedica. Andrew Xanthopoulos reports honoraria from Novartis. Randall C. Starling reports research funding from Covia, Amgen; and is an advisor for and on the steering committee at Cardiac Dimensions, as well as serving on the steering committee for the Novartis PARAGLIDE Trial.